Actinium Pharmaceuticals, Inc. (ATNM) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ATNM Insider Trading Activity
ATNM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Insider Activity of Actinium Pharmaceuticals, Inc.
Over the last 12 months, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Actinium Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $4,372 was made by SETH SANDESH (Chairman & CEO) on 2018‑12‑10.
List of Insider Buy and Sell Transactions, Actinium Pharmaceuticals, Inc.
| 2018-12-10 | SETH SANDESH | Chairman & CEO | 10,000 0.0095% | $0.44 | $4,372 | -37.73% | ||
| 2018-12-10 | O'Loughlin Steve | Principal Financial Officer | 10,000 0.0095% | $0.43 | $4,350 | -37.73% | ||
| 2018-11-19 | Ludwig Dale L. | Chief Scientific Officer | 10,000 0.01% | $0.45 | $4,499 | -31.63% | ||
| 2018-07-17 | SETH SANDESH | CEO | 10,000 0.0094% | $0.79 | $7,900 | -28.76% | ||
| 2018-06-15 | O'Loughlin Steve | Principal Financial Officer | 12,000 0.0109% | $0.50 | $6,000 | +14.08% | ||
| 2018-04-19 | SETH SANDESH | Chairman & CEO | 5,000 0.0045% | $0.38 | $1,900 | +50.20% | ||
| 2018-02-28 | Shetty Ajit | director | 22,730 0.0257% | $0.43 | $9,774 | +25.81% | ||
| 2017-08-02 | SETH SANDESH | Chairman & CEO | 33,333 0.0538% | $0.75 | $25,000 | -3.30% | ||
| 2017-08-02 | Ray Nitya G. | Executive Vice President | 10,000 0.0161% | $0.75 | $7,500 | -3.30% | ||
| 2017-06-15 | SETH SANDESH | Chairman and CEO | 7,500 0.013% | $1.16 | $8,725 | -45.53% | ||
| 2017-06-15 | Berger Mark Stanley | Chief Medical Officer | 5,000 0.0083% | $1.11 | $5,550 | -45.53% | ||
| 2017-06-15 | O'Loughlin Steve | Principal Financial Officer | 3,500 0.0061% | $1.17 | $4,095 | -45.53% | ||
| 2016-12-30 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.88 | $4,400 | +16.57% | ||
| 2016-12-12 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.98 | $4,900 | +5.15% | ||
| 2016-08-31 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 136,853 0.2928% | $1.83 | $251,118 | -34.31% | |
| 2016-08-30 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 56,074 0.1174% | $1.81 | $101,254 | -33.90% | |
| 2016-08-29 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.0529% | $1.72 | $42,875 | -28.89% | |
| 2016-08-26 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.052% | $1.70 | $42,620 | -29.07% | |
| 2016-08-16 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 5,029 0.0107% | $1.72 | $8,652 | -26.18% | |
| 2016-08-15 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4,439 0.0093% | $1.72 | $7,635 | -25.87% |
Insider Historical Profitability
| Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4709561 15.0967% | $7.86M | 0 | 25 | |
| SETH SANDESH | Chairman & CEO | 153333 0.4915% | $256,066.11 | 10 | 0 | <0.0001% |
| DAVE KAUSHIK J | CEO and Interim CFO | 88500 0.2837% | $147,795.00 | 1 | 0 | <0.0001% |
| O'Loughlin Steve | Principal Financial Officer | 35500 0.1138% | $59,285.00 | 3 | 0 | <0.0001% |
| Shetty Ajit | director | 22730 0.0729% | $37,959.10 | 1 | 0 | +25.81% |
| Nicholson, C. David | director | 15000 0.0481% | $25,050.00 | 1 | 0 | <0.0001% |
| Ray Nitya G. | Executive Vice President | 10000 0.0321% | $16,700.00 | 1 | 0 | <0.0001% |
| Ludwig Dale L. | Chief Scientific Officer | 10000 0.0321% | $16,700.00 | 1 | 0 | <0.0001% |
| Berger Mark Stanley | Chief Medical Officer | 5000 0.016% | $8,350.00 | 1 | 0 | <0.0001% |
| TRAVERSA SERGIO | director | 3000 0.0096% | $5,010.00 | 2 | 0 | <0.0001% |
| Steinhart Richard I | director | 2500 0.008% | $4,175.00 | 1 | 0 | <0.0001% |
| MAZANET ROSEMARY | director | 100 0.0003% | $167.00 | 1 | 0 |
Historical Insider Profitability vs. Competitors
$4,613,182 | 103 | -36.00% | $54.55M | |
$15,973,675 | 54 | 5.25% | $53.52M | |
$77,062,892 | 41 | 13.96% | $55.04M | |
$6,787,959 | 35 | 49.84% | $54.62M | |
$18,752,549 | 33 | -28.39% | $51.82M | |
Actinium Pharmaceuticals, Inc. (ATNM) | $241,165 | 22 | -16.72% | $52.1M |
$1,087,418 | 21 | 1.95% | $57.43M | |
$167,476,357 | 20 | -1.54% | $49.87M | |
$32,972,199 | 16 | -10.77% | $57.11M | |
$91,209,456 | 15 | -7.00% | $49.81M | |
$18,535,159 | 14 | 57.32% | $57.09M | |
$3,871,238 | 10 | -30.38% | $52.29M | |
$3,682,258 | 10 | -34.11% | $49.69M | |
$91,549,696 | 8 | -6.55% | $48.86M | |
$478,647 | 7 | 69.41% | $51.68M | |
$119,593,679 | 6 | -21.91% | $52.69M | |
$43,326,461 | 6 | 16.01% | $50.39M | |
$8,470,804 | 6 | -13.28% | $48.86M | |
$762,555 | 4 | -34.52% | $50.15M |
ATNM Institutional Investors: Active Positions
| Increased Positions | 39 | +48.75% | 977,844 | +11.36% |
| Decreased Positions | 32 | -40% | 1M | -15.24% |
| New Positions | 10 | New | 321,985 | New |
| Sold Out Positions | 19 | Sold Out | 762,960 | Sold Out |
| Total Postitions | 87 | +8.75% | 8M | -3.87% |
ATNM Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $3,018.00 | 6.28% | 1.95M | -25,095 | -1.27% | 2025-03-31 |
| Vanguard Group Inc | $2,507.00 | 5.22% | 1.62M | -7,628 | -0.47% | 2024-12-31 |
| Geode Capital Management, Llc | $1,066.00 | 2.22% | 687,853 | +1,700 | +0.25% | 2024-12-31 |
| State Street Corp | $963.00 | 2% | 621,075 | +18,426 | +3.06% | 2024-12-31 |
| Acadian Asset Management Llc | $774.00 | 1.61% | 499,260 | +45,566 | +10.04% | 2024-12-31 |
| Northern Trust Corp | $390.00 | 0.81% | 251,930 | +11,812 | +4.92% | 2024-12-31 |
| Morgan Stanley | $335.00 | 0.7% | 216,134 | +102,443 | +90.11% | 2024-12-31 |
| Los Angeles Capital Management Llc | $332.00 | 0.69% | 213,950 | +42,770 | +24.98% | 2024-12-31 |
| Renaissance Technologies Llc | $295.00 | 0.61% | 190,400 | +63,400 | +49.92% | 2024-12-31 |
| Squarepoint Ops Llc | $284.00 | 0.59% | 183,262 | +37,159 | +25.43% | 2024-12-31 |